Die Ergebnisse der Phase III Studie zu Dabrafenib im Vergleich zu Dacarbazin sind heute im „The Lancet“ verschienen. Der Volltext des Artikels ist auf der Homepage des Journals abrufbar.
In der aktuellen Ausgabe von „Melanoma Resaerch“ sind die Ergebnisse zur ADO-Studie „Best suppotive care vs. DVP“ erschienen. Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient’s choice: a multicentre Dermatologic Cooperative Oncology Group trial. Hofmann MA, Hauschild A, Mohr P, Garbe C, Weichenthal M, … Weiterlesen
Background Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. Methods We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the … Weiterlesen
Background Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma. Methods We … Weiterlesen